Clinical  ||| S:0 E:9 ||| JJ
development  ||| S:9 E:21 ||| NN
of  ||| S:21 E:24 ||| IN
temsirolimus ||| S:24 E:36 ||| NN
,  ||| S:36 E:38 ||| ,
a  ||| S:38 E:40 ||| DT
novel  ||| S:40 E:46 ||| NN
mTOR  ||| S:46 E:51 ||| JJ
inhibitor ||| S:51 E:60 ||| NN
,  ||| S:60 E:62 ||| ,
for  ||| S:62 E:66 ||| IN
treatment  ||| S:66 E:76 ||| NN
of  ||| S:76 E:79 ||| IN
advanced  ||| S:79 E:88 ||| JJ
malignancies  ||| S:88 E:102 ||| FW
